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Abstract
Background: The influx of leukocytes into the central nervous system (CNS) is a key hallmark of the chronic
neuro-inflammatory disease multiple sclerosis (MS). Strategies that aim to inhibit leukocyte migration across the
blood-brain barrier (BBB) are therefore regarded as promising therapeutic approaches to combat MS. As the
CD40L-CD40 dyad signals via TNF receptor-associated factor 6 (TRAF6) in myeloid cells to induce inflammation
and leukocyte trafficking, we explored the hypothesis that specific inhibition of CD40-TRAF6 interactions can
ameliorate neuro-inflammation.
Methods: Human monocytes were treated with a small molecule inhibitor (SMI) of CD40-TRAF6 interactions
(6877002), and migration capacity across human brain endothelial cells was measured. To test the therapeutic
potential of the CD40-TRAF6-blocking SMI under neuro-inflammatory conditions in vivo, Lewis rats and C57BL/6J
mice were subjected to acute experimental autoimmune encephalomyelitis (EAE) and treated with SMI 6877002
for 6 days (rats) or 3 weeks (mice).
Results: We here show that a SMI of CD40-TRAF6 interactions (6877002) strongly and dose-dependently reduces
trans-endothelial migration of human monocytes. Moreover, upon SMI treatment, monocytes displayed a decreased
production of ROS, tumor necrosis factor (TNF), and interleukin (IL)-6, whereas the production of the anti-
inflammatory cytokine IL-10 was increased. Disease severity of EAE was reduced upon SMI treatment in rats, but
not in mice. However, a significant reduction in monocyte-derived macrophages, but not in T cells, that had
infiltrated the CNS was eminent in both models.
Conclusions: Together, our results indicate that SMI-mediated inhibition of the CD40-TRAF6 pathway skews
human monocytes towards anti-inflammatory cells with reduced trans-endothelial migration capacity, and is
able to reduce CNS-infiltrated monocyte-derived macrophages during neuro-inflammation, but minimally
ameliorates EAE disease severity. We therefore conclude that SMI-mediated inhibition of the CD40-TRAF6
pathway may represent a beneficial treatment strategy to reduce monocyte recruitment and macrophage
activation in the CNS and has the potential to be used as a co-treatment to combat MS.
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Background
Multiple sclerosis (MS) is a progressive, inflammatory,
demyelinating disease of the central nervous system
(CNS) that results in the formation of sclerotic plaques in
the white and gray matter, causing clinical symptoms,
such as weakness, numbness, pain, and visual impair-
ments [1]. Although the etiology of MS remains unknown,
the CNS entry of immune cells, especially monocytes
and T cells, plays a pivotal role in the development of
MS [1–3]. Disruption and inflammation of the blood-
brain barrier (BBB) is a prerequisite for leukocyte CNS
entry and can be initiated by reactive oxygen species
(ROS), matrix metalloproteinases (MMPs), angiogenic
factors, inflammatory cytokines, autoantibodies, patho-
gens, and leukocytes themselves via firm adhesion to
brain endothelial cells and subsequent trans-endothelial
migration [4]. After BBB passage, monocyte-derived
macrophages and T cells promote lesion formation and
cause axonal damage [1–3, 5, 6]. In turn, these immune
cells secrete pro-inflammatory cytokines and chemokines
that promote the recruitment of other immune cells,
which amplifies the inflammatory response [1–3, 7]. Strat-
egies that inhibit immune cell migration into the CNS are
therefore promising therapeutic approaches to combat
MS. The majority of current MS therapies such as anti-
very late antigen (VLA)-4 antibodies, MMP inhibitors,
interferons, and corticosteroids can successfully reduce
the relapse rate as well as the development of new inflam-
matory CNS lesions that occur after breakdown of the
BBB in patients [8–12]. However, a drawback of current
therapies is that they target a vital part of the immune sys-
tem, which induces immune-suppressive side effects [13].
Therefore, there is a high and unmet need for the develop-
ment of novel and more specific therapeutic strategies.
The co-stimulatory CD40-CD40L dyad has a critical
role in the development of immune responses and
chronic inflammatory diseases, such as atherosclerosis,
obesity, and rheumatoid arthritis [14]. In MS lesions,
CD40 is expressed on brain endothelial cells, monocytes,
pro-inflammatory (M1) macrophages, astrocytes, and
microglia, and CD40L is highly expressed by T cells found
in the cerebrospinal fluid of MS patients [15–18]. Exposure
of primary human brain microvascular endothelial cells
(BMVECs) to soluble CD40L promoted the expression of
intercellular adhesion molecule (ICAM)-1 and vascular cell
adhesion molecule (VCAM)-1, which led to a fourfold in-
crease in monocyte adhesion to BMVECs [19]. Both
CD40L−/− and CD40−/− mice are protected against experi-
mental autoimmune encephalomyelitis (EAE) [15, 18].
CD40 expressed by CNS-endogenous cells is known to
control the migration and retention of myelin oligodendro-
cyte glycoprotein-reactive T cells in the CNS of mice dur-
ing EAE [20]. Antibody-mediated inhibition of CD40 and
CD40L repressed EAE onset and the severity of disease in
marmoset monkeys and mice. Moreover, when anti-
CD40L antibodies were administered during disease re-
mission in these models, clinical relapses were prevented
[21–24]. However, (long-term) antibody-mediated inhib-
ition of CD40L results in thromboembolic events and/or
immunosuppression [25]. Specific downstream interfer-
ence in the CD40L-CD40 pathway is therefore preferable.
Upon binding of CD40L, CD40 recruits tumor necrosis
factor receptor-associated factors (TRAFs) to exert signal-
ling [25]. The intracellular domain of CD40 contains a
distal binding domain for TRAF2/3/5 and a proximal
domain for TRAF6 [25]. Using mice with site-directed
mutagenesis for the TRAF6 or TRAF2/3/5 binding site on
the CD40 intracellular tail, we demonstrated that CD40-
TRAF6 interactions, and not CD40-TRAF2/3/5 interac-
tions, promote the development of atherosclerosis and
neointima formation [26, 27]. Mice with a deficiency in
CD40-TRAF6 interactions are characterized by decreased
numbers of circulating ly6Chigh monocytes, impaired re-
cruitment of monocytes to the endothelium, and skewing
of macrophages towards the anti-inflammatory (M2)
profile [26]. To exploit the therapeutic potential of the
CD40-TRAF6 axis, we developed small molecule inhibi-
tors (SMIs) of CD40-TRAF6 interactions [28]. SMI
6877002 has been confirmed to have functional specifi-
city for the CD40-TRAF6 and not the CD40-TRAF2/3/
5 pathway. The SMI did not show toxicity in an in vitro
viability assay or in in vivo treatment [28]. SMI 6877002
was proven to successfully reduce metabolic and inflam-
matory complications of diet-induced obesity, peritonitis,
and sepsis [28, 29].
As the CD40L-CD40 dyad plays a critical role in chronic
inflammation and monocyte recruitment and skewing,
which are key elements of neuro-inflammation, we here
aimed to study the effects of SMI-mediated blockage of
the CD40-TRAF6 interaction on human monocyte trans-
endothelial migration and activation in vitro. In addition,
we investigated the effect of our CD40-TRAF6-blocking
SMI on neuro-inflammation in vivo.
Methods
Isolation of human monocytes and treatments
Human blood monocytes were isolated from buffy
coats of healthy donors (n = 5) (Sanquin blood bank,
Amsterdam, The Netherlands, upon written informed
consent with regard to scientific use) by Ficoll gradient
and CD14-coated beads as described previously [30].
The human brain endothelial cell line hCMEC/D3 [31]
was grown in endothelial cell basal medium-2 supple-
mented with human epidermal growth factor (hEGF),
hydrocortisone, GA-1000, fetal bovine serum (FBS), vas-
cular endothelial growth factor (VEGF), human fibroblast
growth factor (hFGF-B), R3-insulin-like growth factor
(IGF)-1, ascorbic acid, and 2.5% fetal calf serum (EGM-2,
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Lonza, Basel, Switzerland). Endothelial cells (ECs) were
grown to confluence in 96-well plates. Monocytes were
incubated with vehicle (DMSO 0.16%) or the small
molecule inhibitor (SMI) 6877002 (1–10 μM) [28, 29]
for 1 h, after which CD40 signalling was activated using
the agonistic CD40 antibody G28.5 (30 μg/ml) com-
bined with IFN-γ (5 ng/ml) for 16 h. In another experi-
ment, monocytes were incubated with G28.5 (30 μg/ml)
for 1 h before treatment with SMI 6877002 (1–10 μM)
for 16 h. To study the role of ROS in CD40-TRAF6-
induced monocyte migration, 50 μM luteolin (a flavonoid
with ROS scavenging function, able to inhibit EAE and
myelin phagocytosis [32, 33]) (Sigma-Aldrich, St. Louis,
MO, USA) was added to the vehicle/SMI-pretreated
monocytes 1 h before the migration experiment.
In vitro trans-endothelial migration assay
We used two established protocols for the measurement
of human monocyte migration across brain endothelial
cells using a Transwell system [34] and/or time-lapse
video microscopy [35] with minor modifications. For
Transwell migration experiments, we used a Transwell
system (Costar, Corning, Amsterdam, The Netherlands)
with polycarbonate filter pore size of 5 μm, which were
coated with collagen type 1 (Sigma-Aldrich, Zwijndrecht,
The Netherlands). The hCEMC/D3 cells were seeded at
a concentration of 1 × 104 cells per well in endothelial
cell basal medium-2 (Lonza) supplemented with 2.5%
FCS (Lonza) and were cultured to confluent monolayers.
After extensive washing, monocytes were re-counted
and suspended in culture medium (7.5 × 105 cells/ml)
and were added to brain endothelium monolayers and
incubated for 8 h. To determine the number of mi-
grated cells, trans-migrated cells were transferred to
FACS tubes, and 20,000 beads (Beckman Coulter, USA)
were added to each sample. Samples were analysed
using a FACSCalibur (Becton Dickinson, Belgium), and
the number of migrated monocytes was determined
based on 5000 gated beads. The absolute number of
migrated monocytes is presented compared to the total
number of monocytes added to the upper chamber as
described [36].
For time-lapse video microscopy experiments, mono-
cytes were added to brain endothelial monolayers and
the number of migrated monocytes was assessed after
4 h using an inverted phase-contrast microscope (×40
magnification, Nikon Eclipse TE300) housed in a
temperature-controlled (37 °C), 5% CO2 gassed chamber
(manufactured for this purpose). A field of 200 μm2 was
randomly selected and recorded for 10 min at 50 times
normal speed using a color video 3CCD camera (Sony,
using a CMAD2 adapter) coupled to a time-lapse video
recorder (Sony SVT S3050P). After recording, tapes were
replayed at normal speed and analysed by enumerating
the number of cells within the field that had migrated
through the monolayer. All experiments were performed
in triplicate with at least three different donors.
Dihydrorhodamine assay
ROS production by monocytes was measured using
dihydrorhodamine (DHR) (Sigma-Aldrich, Munich,
Germany), which reacts with ROS in a peroxidase-like
reaction to yield fluorescent rhodamine 123 [37]. After
incubation with the SMI and stimulation with the agon-
istic CD40 antibody G28.5 as described above, cells were
rinsed twice with RPMI, re-counted (7.5 × 105 cells/ml)
and incubated for 30 min at 37 °C with 0.5 μM DHR in
RPMI medium. After that, cells were rinsed twice with
PBS/BSA 0.1% and transferred to FACS tubes. Analysis
of cells fluorescent for rhodamine 123 was performed by
flow cytometry with excitation at 488 nm and the emit-
ted fluorescence collected at 525 nm.
Analysis of cytokine profiles
The production of pro- and anti-inflammatory mediators
was assessed by enzyme-linked immunosorbent assay
(ELISA) in cell-free supernatants of vehicle- or SMI-
treated CD40-stimulated monocytes using commercial
kits for human IL-10, IL-6, and TNF-α CytoSet ELISA
kit (Biosource, Nivelles, Belgium) according to the man-
ufacturer’s protocol. The samples were measured using a
Luminex 200 (Bio-Rad, Hercules, CA, USA).
Flow cytometry
SMI-treated and untreated human monocytes were
incubated with primary antibody (50 mg/ml Nanogam,
Sanquin, The Netherlands) diluted in FACS buffer (PBS
containing 0.5% bovine serum albumin (BSA) and 2 mM
EDTA) to prevent non-specific binding of antibodies to
the Fc receptors. Cells were then incubated with fluo-
rescently labeled secondary antibodies CD14, CD16,
HLA-DR, CD80 (BD, Breda, The Netherlands), and
CD86 (BioLegend, San Diego, CA, USA), and staining
was analysed by flow cytometry (FACSCanto II, BD
Biosciences, Breda, The Netherlands) and FlowJo soft-
ware version 7.6.5 (Tree Star).
EAE induction rats
Eight-week-old male Lewis rats were obtained from
Harlan and maintained at the animal facility of the VU
University Medical Center. The animals had ad libitum
access to food and water and were housed under a 12-h
light/dark cycle.
To induce EAE, rats were injected subcutaneously
with 20 μg myelin basic protein (MBP) isolated from
guinea pig brain and spinal cord (Harlan Laboratories,
Horst, The Netherlands) in PBS mixed with complete
Freund’s adjuvant (CFA; 4 mg/ml Mycobacterium
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tuberculosis H37Ra; Difco Laboratories, Detroit, MI,
USA). A control group without EAE induction was in-
cluded (n = 6). EAE animals were treated by intraperito-
neal (i.p.) injection with the vehicle (0.05% Tween 80,
2% DMSO in saline) (n = 11) or with 10 μmol/kg SMI
6877002 (n = 11) from days 6 to 11 after the induction
of EAE. This phase of the disease is mainly character-
ized by the recruitment of inflammatory cells to the
CNS. Neurological symptoms were scored daily and
graded from 0 to 5: 0 = no neurological abnormalities;
0.5 = partial loss of tail tonus; 1 = complete loss of tail
tonus; 2 = hind limb paresis; 3 = hind limb paralysis; 4
= paralysis up to the diaphragm; 5 = death. Body weight
was measured daily. Animals were sacrificed 14 and
20 days after induction of EAE. All the experimental
procedures were approved by the Ethical Committee
for Animal Experiments of the VU University Medical
Center (VUMC). Scoring of clinical symptoms was per-
formed by an observer who was blinded to the experi-
mental conditions.
Histology and immunohistochemistry of rat cerebellum
and spinal cord
The brain was collected, snap-frozen in liquid nitrogen,
and stored at −80 °C. The spinal cord was fixed in 4%
paraformaldehyde and embedded in paraffin. Inflamma-
tion of the spinal cord was graded on 4-μm haematoxylin-
eosin (H&E)-stained sections. Immunohistochemistry on
the spinal cord was performed for CD68 (1:200, poly-
clonal, Abcam Inc., Cambridge, MA, USA) and for CD3
(1:200, clone G4.18, eBioscience, San Diego, CA, USA).
The cerebellum was embedded in Tissue Tek, and 6-μm
sections were used for staining with rabbit anti-laminin
(1:200, clone 6e3, EY Laboratories, San Mateo, USA) to
localize CNS infiltrates, ED1 (1:100, AbD Serotec, Puch-
heim, Germany) to detect macrophages, or R7.3 (1:85, BD
Biosciences, San Jose, CA, USA) to detect T cells. Nuclei
were visualized by DAPI (Invitrogen, Eugene, USA). All
other organs were analysed following H&E staining.
Analyses were performed by an observer who was blinded
to the experimental conditions.
RNA isolation and qPCR of rat spinal cord
Total RNA was extracted from the spinal cord using
TRIzol (Invitrogen, Carlsbad, CA, USA) and reverse-
transcribed using an iScript cDNA synthesis kit (Bio-
Rad, Veenendaal, The Netherlands). Quantitative (q)PCR
was performed with a SYBR Green PCR kit (Applied
Biosystems, Leusden, The Netherlands) on a ViiA7 real-
time PCR system (Applied Biosystems, Leusden, The
Netherlands). Expression levels of transcripts obtained
with real-time PCR were normalized to GAPDH expres-
sion levels. The following rat primers were used: GAPDH
FW: 5′-AGGTTGTCTCCTGTGACTTC-3′, GAPDH RV:
5′-CTGTTGCTGTAGCCATATTC-3′, CD40 FW: CD40
RV: 5′-CTTAACCTGAAGCCCTTGATTG-3′, CD80 5′-
TTCCACGTCTCAGGTTCATTC-3′, CD80 RV: 5′-GTA
ATCACAGGACAGCAATGC-3′, CD86 FW: 5′-TCTGT
GCTGTCTCTTTCTGC-3′, CD86 RV: 5′-TTGATCGA
CTCGTCAACACC-3′, TNF FW: 5′-CTTCTCATTCCT
GCTCGTGG-3′, TNF RV: 5′-TGATCTGAGTGTGAG
GGTCTG-3′, NOS2 FW: 5′-GGAGCAGGTTGAGGAT-
TACTTC-3′, NOS2 RV: 5′-TCAGAGTCTTGTGCCTT
TGG-3′, MMP2 FW: 5′-AGGGCACCTCTTACAACAG
C-3′, MMP2 RV: 5′-CCCGGTCATAATCCTCGGTG-3′,
MMP9 FW: 5′-GATCCCCAGAGCGTTACTCG-3′, MM
P9 RV: 5′-GTTGTGGAAACTCACACGCC-3′.
EAE induction mice
To investigate the effects of extended 6877002 treatment
in EAE, a second model was used. Ten-week-old female
C57BL/6J mice were obtained from Charles River Labora-
tories and maintained at the animal facility of the Aca-
demic Medical Center, Amsterdam. The animals had ad
libitum access to food and water and were housed under a
12-h light/dark cycle. They were treated daily by i.p. injec-
tion with the vehicle (0.05% Tween 80, 2% DMSO in
saline) (n = 14) or with 10 μmol/kg SMI 6877002 (n = 14)
starting 3 days before EAE induction until 17 days after
the induction of EAE. On day 0, mice were immunized
subcutaneously with 200 μg of a myelin oligodendrocyte
glycoprotein peptide (MOG35-55) emulsified in CFA sup-
plemented with 4 mg/ml M. tuberculosis H37Ra (Hooke
Laboratories, Lawrence, MA, USA). Mice were injected
i.p. on days 0 and 1 with 400 ng pertussis toxin. A control
group without EAE induction was included (n = 6).
Neurological symptoms were monitored daily using the
grading scale as follows: 0 = no neurological abnormalities;
0.5 = partial loss of tail tonus; 1 = complete loss of tail
tonus; 2 = hind limb paresis; 3 = partial hind limb paraly-
sis; 4 = complete hind limb paralysis; 4.5 = paralysis up to
the diaphragm, 5 = death. Body weight was measured
daily, and the animals were sacrificed 17 days after induc-
tion of EAE. All the experimental procedures were ap-
proved by the Ethical Committee for Animal Experiments
of the Academic Medical Center, Amsterdam (AMC).
Scoring of clinical symptoms was performed by an obser-
ver who was blinded to the experimental conditions.
Flow Cytometry
Blood was obtained by cardiac puncture and collected
using EDTA-filled syringes. The spleen and lymph nodes
were collected. Erythrocytes in the blood and spleen were
removed by incubation with hypotonic lysis buffer (8.4 g
of NH4Cl and 0.84 g of NaHCO3 per litre of distilled
water). To prevent non-specific binding of antibodies to
the Fc receptor, all cell suspensions were incubated with a
CD16/32 antibody (eBioscience, San Diego, CA, USA)
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prior to labelling. CD45, CD19, CD8, FoxP3 (eBioscience,
San Diego, CA, USA), CD3 (BioLegend, San Diego, CA,
USA), CD11b, and CD4 (BD, Breda, The Netherlands)
antibodies were incubated with the indicated tissues.
Staining was analysed by flow cytometry (FACSCanto II,
BD Biosciences, Breda, The Netherlands) and FlowJo
software version 7.6.5 (Tree Star).
Histology and immunohistochemistry of the mouse
cerebellum
The cerebellum was collected and fixed in 4% parafor-
maldehyde and embedded in paraffin. Inflammation
was graded on 4-μm-thick H&E-stained sections. Immu-
nohistochemistry was performed for Mac3 (BD, Breda,
The Netherlands) and CD3 (AbD Serotec, Puchheim,
Germany). Per section, 8–12 pictures were taken to in-
clude the complete cerebellum surface and analysed by an
observer who was blinded to the experimental conditions.
RNA isolation and qPCR of mice spinal cord
RNA isolation of the spinal cord, cDNA synthesis, and
qPCR were performed as described above. Expression
levels of transcripts obtained with real-time PCR were
normalized to the mean expression levels of the three
housekeeping genes GAPDH, CycloA, and Rplp0. The
following mouse primers were used: GAPDH FW: 5′-
CAACTCACTCAAGATTGTCAGCAA-3′, GAPDH RV:
5′-TGGCAGTGATGGCATGGA-3′, CycloA FW: 5′-TT
CCTCCTTTCACAGAATTATTCCA-3′, CycloA RV: 5′-
CCGCCAGTGCCATTATGG-3′, Rplp0 FW: 5′-GGAC
CCGAGAAGACCTCCTT-3′, Rplp0 RV: 5′-GCACATC
ACTCAGAATTTCAATGG-3′, IFN-γ FW: 5′-GAGGA
ACTGGCAAAAGGATGG-3′, IFN-γ RV: 5′-TGTTGCT
GATGGCCTGATTG-3′, IL-17 FW: 5′-TCCCTCTGT
GATCTGGGAAG-3′, IL-17 RV: 5′-CTCGACCCTGA
AAGTGAAGG-3′, FoxP3 FW: 5′-CCCAGGAAAGACA
GCAACCTT-3′, FoxP3 RV: 5′-TTCTCACAACCAGG
CCACTTG-3′. TNF FW: 5′-CATCTTCTCAAAATTCG
AGTGACAA-3′, TNF RV: 5′-TGGGAGTAGACAAGG
TACAACCC-3′, IL-10 FW: 5′-TTTGAATTCCCTGGG
TGAGAA-3′, IL-10 RV: 5′-CTCCACTGCCTTGCTCT
TATTTTC-3′, MCP-1 FW: 5′-AGCACCAGCCAACTC
TCACT-3′, and MCP-1 RV: 5′-CGTTAACTGCATCT
GGCTGA-3′.
Statistical analysis
Results are presented as mean ± SEM. Data were analysed
by Student’s t test, clinical EAE scores were analysed by
ANOVA and Bonferroni post-tests, and the clinical
parameters were analysed by a non-parametric (Mann-
Whitney) test. The log-rank test was used for survival
analysis. Calculations were performed using GraphPad
Prism 5.0 software (GraphPad Software, Inc., La Jolla,
CA, USA). P values <0.05 were considered statistically
significant.
Results
Inhibition of CD40-TRAF6 interactions by SMI 6877002
reduces trans-endothelial migration of human monocytes
and ROS production by these cells
As migration of inflammatory cells across the BBB repre-
sents a pathological hallmark of MS, we analysed the ef-
fects of the CD40-TRAF6-blocking SMI on monocyte
migration across an in vitro BBB [31]. Activation of CD40
signalling in monocytes using the agonistic CD40 anti-
body G28.5 and IFN-γ increased their trans-endothelial
migration across non-activated EC by 210% (1 h vehicle
pretreated) or 146% (Fig. 1a). When monocytes were
Fig. 1 SMI treatment of monocytes inhibits CD40-induced trans-endothelial migration by limiting ROS production. Human monocytes were treated
with either SMI 6877002 (1–10 μM) or vehicle for 1 h and stimulated with G28.5 (agonistic CD40 antibody) for 16 h, or pretreated with G28.5 for 1 h
and then stimulated with SMI 6877002 for 16 h. a Monocyte trans-endothelial migration was studied in vitro using hCMEC/D3 cells by Transwell
migration [31]. b ROS production measured as mean fluorescence intensity (MFI) of rhodamine 123. c CD40-induced monocyte migration in the
presence or absence of the ROS scavenger luteolin (50 μM), measured in time-lapse migration. Experiments were performed in triplicate using buffy
coats from 3 (1A), 4 (1B), or 3 (1C) human donors, and results are presented as the mean ± SEM. */#P < 0.05, **/##P < 0.01,***/###P < 0.001 as
determined by Student’s t test. #luteolin vs control
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treated with the SMI (before or after CD40 activation),
a dose-dependent reduction in trans-endothelial migra-
tion was observed (Fig. 1a). In contrast, SMI treatment
of brain endothelial cells had no effect on monocyte
trans-endothelial migration (data not shown), suggest-
ing that the SMI specifically affects CD40 on mono-
cytes and does not block CD40 signalling in endothelial
cells. Cell viability was unaffected by the SMI treatment
(data not shown).
Reactive oxygen species play an important role in
neurodegenerative diseases like MS. Pro-inflammatory
mediators and oxidizing radicals are produced by
adherent monocytes, infiltrating macrophages and acti-
vated microglia [38]. These locally generated ROS
induce BBB disruption and enhance leukocyte migra-
tion in the initial phase of MS lesion formation [39]. To
assess whether SMI treatment affects ROS production
by human monocytes, we activated CD40 in the pres-
ence or absence of the CD40-TRAF6-blocking SMI and
measured ROS production. As shown in Fig. 1b, CD40-
induced ROS production by monocytes was signifi-
cantly reduced by treatment with SMI 6877002 (35.1%).
To address whether the inhibiting effects of SMI
6877002 on monocyte migration were ROS dependent,
we introduced the flavonoid luteolin in our in vitro
BBB system. Luteolin decreased the trans-endothelial
migration capacity of non-treated monocytes, as de-
scribed before [33]. Notably, CD40-induced monocyte
migration was blocked when these monocytes were
treated with luteolin, revealing an important role for ROS
in CD40-induced monocyte trans-endothelial migration
(Fig. 1c). Interestingly, luteolin had no effect on the migra-
tion of SMI-treated monocytes, which is in line with our
assumption that both have a similar mechanism, which is
inhibition of ROS production.
Together, these data indicate that SMI-mediated inhib-
ition of CD40-TRAF6 interactions in monocytes impairs
the recruitment of these cells, to some extent in a ROS-
dependent manner.
Small molecule inhibitors of the CD40-TRAF6 interaction
reduce inflammation of human monocytes
Human monocytes can be divided into a classical, CD14+
pro-inflammatory subset, a non-classical CD16+ subset,
and an intermediate subset positive for both CD14 and
CD16 [35]. To assess whether SMI treatment affects the
inflammatory phenotype of monocytes, we performed
flow cytometry on the cells and ELISA on the super-
natant. SMI treatment results in a relative smaller sub-
set of CD14+ monocytes and more intermediate CD14
+/CD16+ monocytes (Fig. 2a). Moreover, SMI treatment
results in trends towards reduced HLA-DR, CD80, and
CD86 expression in the classical monocyte subset
(CD14+) compared to the vehicle-treated monocytes
(Fig. 2b). Besides affecting ROS production, SMI
6877002 was also able to reduce CD40-induced TNF
production in human monocytes, both on the protein
level (Fig. 2c) and the transcript level (12.4-fold in-
crease in vehicle-treated monocytes vs 7.4-fold increase
in SMI-treated monocytes compared to untreated cells,
data not shown). Moreover, SMI treatment reduced IL-
6 levels and increased the levels of the anti-
inflammatory cytokine IL-10 (Fig. 2c).
Collectively, these data indicate that our CD40-
TRAF6-inhibiting SMI is capable of antagonizing the
CD40-induced pro-inflammatory profile of monocytes,
and increasing IL-10 production, thereby generating a
more anti-inflammatory monocyte phenotype, less cap-
able of traversing the brain endothelial barrier in vitro.
SMI 6877002 treatment ameliorates EAE in rats
To study the effects of our SMI on neuro-inflammation
in vivo, we induced acute EAE in rats and treated them
daily from days 6 to 12 with 10 μM/kg SMI 6877002, or
vehicle. All EAE-induced rats developed clinical symp-
toms of EAE and none of the animals died due to EAE
(Table 1). Body weight was not affected by the treatment
(Table 1), and haematoxylin and eosin staining of the
spleen, liver, heart, lung, gastrointestinal tract, kidney,
bladder, and lymph nodes revealed no toxic, immuno-
suppressive, or thromboembolic side effects of the SMI.
The peak disease severity was significantly reduced in
rats treated with SMI 6877002 compared to vehicle-
treated rats, and the cumulative score (AUC) was
smaller, but not significantly reduced, in the SMI-treated
rats (Fig. 3a and Table 1). The SMI treatment had no
significant effect on the day of onset of EAE symptoms.
These in vivo findings suggest that SMI 6877002 is
able to ameliorate the severity of EAE.
Blocking CD40-TRAF6 interactions limits macrophage in-
flux into the cerebellum of EAE-induced rats and reduces
inflammation in the spinal cord
To determine the phenotype and localization of CNS
infiltrates during EAE, we performed immunohisto-
chemistry on the cerebellum of three rats sacrificed at
the peak of disease (day 14 after EAE induction). Upon
SMI treatment, we observed reduced numbers of mac-
rophages and/or activated microglia (ED1+ cells) in
white matter lesions and we detected accumulation of
monocyte-derived macrophages in the perivascular
spaces whereas in vehicle-treated EAE animals, macro-
phages and/or activated microglia were predominantly
present in the brain parenchyma (Fig. 3b). SMI treat-
ment did not affect the localization or amount of T
cells (R7.3+ cells) as these cells were found in both the
perivascular spaces and white matter lesions in all
groups (Fig. 3b). Accordingly, transcript levels of TNF,
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nitric oxide synthase (NOS2), MMP9, and CD86 in the
spinal cord at the peak of the disease (n = 3 per group)
showed a slight, but not significant, reduction (Fig. 3c).
Further analysis of the spinal cords obtained from the
rats sacrificed after recovery of EAE revealed similar
findings. The numbers of macrophages and/or activated
microglia (CD68+ cells) and T cell (CD3+ cells) accumu-
lation in the spinal cord after recovery of EAE were
significantly lower in the SMI-treated group compared to
the non-treated controls (Fig. 3d), and transcript levels of
Table 1 Clinical parameters of rats subjected to EAE and treated with vehicle or SMI 6877002
Clinical parameter Vehicle SMI 6877002 Statistics
Incidence (%) 100 100
Survival (%) 100 100
AUC 10.6 8.7 P = 0.0804
Mean clinical score (day 13) 2.9 2.0 P = 0.1160
Mean day of onset 11.1 11.5 P = 0.4740
Mean peak disease severity 3.4 2.9 P = 0.0184
% Body weight loss (day 12 compared to day 0) 5.4 4.7 P = 0.2636
Treatment with SMI 6877002 reduced the cumulative score (AUC), the mean clinical score on day 13, and the peak disease severity compared to vehicle-treated
rats. P values <0.05 were considered statistically significant, as determined by the non-parametric Mann-Whitney U test for disease scores or Student’s t test for
body weight
Fig. 2 CD40-TRAF6-inhibiting SMI 6877002 improved the inflammatory phenotype of monocytes. Human monocytes were treated with SMI
6877002 (2.5 μM) for 1 h and stimulated with G28.5 (agonistic CD40 antibody) for 16 h. a CD14+ (classical), CD14+/CD16+ (intermediate), and
CD16+ (non-classical) subsets of monocytes were measured by flow cytometry. b HLA-DR, CD80, and CD86 mean fluorescent intensity (MFI)
measured in the classical monocyte subset (CD14+) by flow cytometry. c TNF, IL-6, and IL-10 production were measured by ELISA. Experiments
were performed in triplicate using buffy coats of 2 (flow cytometry) or 4 (ELISA) human donors, and results are presented as the mean ± SEM. *P
< 0.05, **P < 0.01, ***P < 0.001 as determined by Student’s t test
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TNF, NOS2, and MMP9 were reduced (Additional file 1:
Figure S1).
Thus, the ability of SMI 6877002 to reduce the number
of macrophages and/or activated microglia in the brain
parenchyma and to diminish gene expression of pro-
inflammatory markers in the spinal cord may explain the
observed decrease in the severity of clinical signs in the
SMI-treated animals compared to untreated EAE animals.
Fig. 3 SMI 6877002 treatment ameliorates severe paralysis in rats subjected to EAE. a EAE was induced, and animals were treated with 10 μmol/
kg SMI 6877002 or vehicle from days 6 to 11 after induction. Clinical scores were observed daily. Experiments were performed with 6 animals in
the control group and 11 animals in the EAE and SMI groups. b Immunofluorescence analysis of rat EAE cerebellum to determine macrophage
and T cell infiltration into the CNS parenchyma. Sections were stained for ED1 (in red for macrophages), R7.3 (in red for T cells), and laminin (in
green for localization). Representative images from three animals per group sacrificed at the peak of the disease. Scale bar 25 μm. c Gene expression in rat
spinal cord during peak of disease was measured by qPCR. mRNA expression levels of TNF, NOS2, MMP9, CD80, CD86, and CD40 presented as relative
expression compared to GAPDH. Expression was measured in three animals per group. d Quantified numbers of CD68 (for macrophages)- and CD3 (for T
cells)-positive immune cell infiltrates in spinal cord tissues collected at day 20 of EAE. For each animal, the amount of infiltrates was counted on four levels,
5 mm between sections. Results are presented as the mean ± SEM. *P< 0.05, ***P< 0.001 as determined by Student’s t test
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Blocking CD40-TRAF6 interactions does not ameliorate
EAE in mice, but decreases macrophage accumulation in
the CNS
To confirm the protective effect of SMI 6877002 in a
different model of EAE, EAE was induced in C57BL/6J
mice. In this model, mice were treated with the SMI or
vehicle starting 3 days before EAE induction until sacri-
fice at the peak of clinical symptoms. Body weight was
not significantly affected by the treatment (Table 2). Al-
though SMI-treated mice had a slightly better survival
compared to vehicle-treated mice, SMI treatment had
no effect on disease severity or day of onset of disease in
this model (Fig. 4a and Table 2).
However, in the cerebellum of the SMI 6877002-treated
mice, we observed a significant reduction in numbers of
Mac3+-stained cells compared to the vehicle-treated mice
(Fig. 4b), indicating reduced macrophage accumulation
and/or microglia activity. There was no difference in the
number of CD3+ cells infiltrated in the cerebellum
(Fig. 4b), showing that, in line with the rat experiments,
the SMI inhibits macrophage infiltration, but not T cell in-
filtration, into the CNS parenchyma.
Flow cytometry on the lymph nodes (LN) of the SMI-
and vehicle-treated animals subsequently showed no dif-
ference between the groups in the total T cell percentage
(CD3+) of the leukocyte population, but we observed a
change in CD4/CD8 T cell balance. CD4+ T cells are
found to be more important in the induction of EAE
through their production of IL-17, while CD8+ T cells ex-
press higher levels of the suppressive cytokine IL-10 and
have a more regulatory role in the later stage of EAE [40].
SMI-treated mice had proportionally less CD4+ T helper
cells and more CD8+ cytotoxic T cells in the lymph nodes
compared to vehicle-treated mice (Fig. 4c), suggesting a
shift from EAE-inducing T cells towards more suppressive
T cells. The percentage of regulatory T cells (FoxP3+) was
not affected by the SMI treatment (Fig. 4c). Analysis of
immune cell subsets in the blood and spleen showed no
effect of SMI treatment in EAE mice on circulating leuko-
cytes (Additional file 2: Figure S2a,b).
The spinal cords of the mice sacrificed at the peak of
EAE were used for gene expression analysis. mRNA ex-
pression of IL-10, TNF, MCP1, IFN-γ, IL-17, and FoxP3
in the spinal cord did not differ between the groups
(Additional file 3: Figure S3).
Taken together, these data show that our CD40-
TRAF6-blocking SMI predominantly impairs monocyte
and macrophage recruitment into the CNS, reduces
neuro-inflammation, and can decrease disease severity in
a rat model of EAE and improve survival in a mouse
model of EAE. Moreover, SMI treatment can direct the
T cell phenotype in the lymph nodes towards a more
EAE-protective CD8+ subtype.
Discussion
Antibody-mediated inhibition of CD40L or CD40 is able
to reduce the severity of inflammatory diseases. Patients
involved in phase I/II trials who received anti-CD40L-
blocking therapy for proliferative lupus glomeruloneph-
ritis, multiple myeloma, non-Hodgkin’s lymphoma, and
systemic lupus erythematosus showed clinical improve-
ment [41–45]. However, all clinical trials were halted
after the report that anti-CD40L treatment bears the risk
of the development of thromboembolic events [46, 47].
After a successful pilot study with anti-CD40L mAb
(IDEC-131) in 15 MS patients (treatment with anti-
CD40L revealed a profound reduction in clinical relapse
rate in relapsing-remitting MS), a phase II trial with 46
MS patients was launched by Lloyd Kasper and
Randolph Noelle in 2002 but was halted soon after a
case of severe thromboembolism occurred in a similar
trial in Crohn’s disease patients [48, 49]. Another risk of
anti-CD40L or anti-CD40 therapy is the development of
immune-suppressive side effects [50].
To circumvent these complications, specific down-
stream interference in the CD40L-CD40 pathway is pref-
erable. Therefore, in this study, we suppressed the CD40-
CD40L dyad with a small molecule inhibitor that was gen-
erated to target the interaction between CD40 and TRAF6
and leave CD40-TRAF2/3/5 interactions intact [28]. SMI
Table 2 Clinical parameters of mice subjected to EAE and treated with vehicle or SMI 6877002
Clinical parameter Vehicle SMI 6877002 Statistics
Incidence (%) 93.3 100.0
Survival (%) 86.7 100 P = 0.1641
AUC 12.75 13.39 P = 0.3461
Mean clinical score (day 15) 2.9 2.8 P = 0.9257
Mean day of onset 12.1 12.6 P = 0.6487
Mean peak disease severity 3.4 3.3 P = 0.8853
% Body weight loss (day 16 compared to day 0) 12.2 12.1 P = 0.6548
Treatment with SMI 6877002 has no significant effect on clinical parameters of EAE in mice. P values <0.05 were considered statistically significant, as determined
by the log-rank test for survival, the non-parametric Mann-Whitney U test for disease scores, or Student’s t test for body weight
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6877002 was designed using a structure-based virtual lig-
and screen [28, 29] and has been shown to be an efficient
and specific inhibitor of CD40-TRAF6 interactions in
mice both in vitro and in vivo [28]. This SMI has proven
to reduce adipose tissue inflammation, improve insulin
resistance in diet-induced obesity, and reduce peritonitis
and polymicrobial sepsis in mice [28, 29].
CD40 is known to be an activator of ROS production
[51], and ROS is a strong driver of monocyte recruit-
ment [39]. By treating monocytes with superoxide, van
Fig. 4 Prolonged SMI treatment does not affect EAE development in mice. Mice were treated with vehicle or 10 μmol/kg SMI 6877002 starting 3 days
prior to EAE induction until 17 days after immunization. a Clinical scores of mice treated with vehicle or SMI 6877002. Experiments were performed
with 14 animals in the vehicle- and SMI-treated groups and 6 control animals without EAE induction. b SMI 6877002 treatment reduces the percentage
of Mac3+ cells in the cerebellum of EAE mice at the peak of disease (scale bar Mac3 staining 400 μm), but has no effect on T cell infiltration into the
cerebellum (scale bar CD3 staining 200 μm). c Flow cytometric analysis demonstrates that SMI 6877002 treatment results in a shift in the CD4/CD8 T
cell balance in lymph nodes. Analysis was performed in lymph nodes of six animals per group sacrificed at the peak of disease. Results are presented
as the mean ± SEM. *P < 0.05, ***P < 0.001 as determined by Student’s t test
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der Goes and colleagues could show that ROS play a key
role in driving monocyte adhesion and trans-migration
across endothelial cells [39]. Here we showed that the
CD40-TRAF6-inhibiting SMI prevents ROS production
by human monocytes and thereby decreases their trans-
endothelial migration capacity.
In addition, SMI-treated monocytes produced less TNF
upon CD40 activation. TNF is well known for its proper-
ties to activate brain endothelium and to increase vascular
permeability of the BBB, leading to leukocyte trans-
endothelial migration, entry of antigens, and activation of
microglia [4]. Not only did our SMI prevent the trans-
endothelial migration capacity of monocytes, but the SMI
also changed the phenotype of the monocyte itself
towards a more anti-inflammatory cell type with less
CD14+ monocytes, reduced HLA-DR, CD80, and CD86
expression, and increased production of IL-10. Skewing of
the monocyte phenotype towards a less inflammatory pro-
file upon SMI treatment together with the ability of the
SMIs to reduce migration of monocytes across the BBB is
what may ultimately lead to a reduction in inflammatory
lesions and/or axonal damage in MS patients.
It was previously shown that both CD40L−/− and
CD40−/− mice are protected against experimental auto-
immune encephalomyelitis (EAE) [15, 18]. In addition to
this, anti-CD40L antibody treatment, when administered
to mice at the time of EAE induction, blocked the devel-
opment of acute disease. Treatment at the peak of acute
disease resulted in a marked reduction in the relapse
rate with fewer mice exhibiting clinical signs of relapse
in the anti-CD40L antibody-treated group [24]. Treat-
ment with anti-CD40L mAb around day 6 and day 9
after EAE induction still resulted in blockade of disease
by 80 and 67%, respectively, as compared with the
complete inhibition (100%) in animals treated with anti-
CD40L mAb around day 2 [18].
To study the effects of our SMI on neuro-
inflammation in vivo, we used the EAE animal model for
MS in Lewis rats and C57BL/6J mice. Upon induction of
EAE, we demonstrated that rats treated with SMI
6877002 had significant reduced disease severity com-
pared to vehicle-treated rats. The rats were treated with
the SMI starting 6 days after induction of EAE and not
at the induction of EAE. We selected this moment based
on our in vitro findings in the BBB model, showing that
our SMI is able to reduce monocyte migration and acti-
vation. As the target of our treatment was the later-
occurring activation and migration of monocytes instead
of the early activation of T cells, we started the treat-
ment after EAE induction. SMI treatment resulted in
modest reduction in clinical symptoms, comparable to
what Howard et al. and Gerritse and colleagues found in
mice when using an anti-CD40L antibody 6–9 days after
induction of EAE [18, 23, 24]. Interestingly, after SMI
treatment, we were able to show that monocyte-derived
macrophages did not enter the CNS parenchyma as nor-
mally seen during EAE, but stay ‘trapped’ in the perivas-
cular space. These findings are in accordance with
research of Laman and co-workers, as they showed that
in the CNS of anti-CD40 mAb-treated marmoset mon-
keys with EAE, most infiltrates were found in the peri-
vascular space and only occasionally in the parenchyma
[21]. Owen and co-workers further showed that when
immune cells stay trapped in the CNS parenchyma, EAE
did not occur [52]. Quantification of immune cells in
spinal cord tissues revealed less CD68- and CD3-positive
accumulated cells in SMI 6877002-treated rats com-
pared to the vehicle-treated EAE animals after recovery
of EAE. These results are in accordance with our in vitro
data that showed that SMI treatment of monocytes af-
fects their migration capacity. The outcomes of our
study with SMI- and vehicle-treated rats are in line with
previous studies using anti-CD40L-blocking antibodies
as this resulted in a reduction in spinal cord cell infiltra-
tion and inflammation and prevented demyelination
[23]. SMI 6877002 treatment of EAE rats in the present
study resulted in reduced severity of clinical EAE symp-
toms, which is most likely explained by reduced mono-
cyte migration into the CNS parenchyma. In mice
treated with our SMI, no effects on clinical parameters
were observed, although macrophage infiltration into
the CNS parenchyma was reduced as well.
A possible explanation for the mild effects observed
with SMI 6877002 in EAE could be the partial blockade
of the CD40 signalling. Our SMI only blocks the CD40-
TRAF6 pathway and leaves the CD40-TRAF2/3/5
signalling intact. This is preferable to minimize immune-
suppressive side effects, but the CD40-TRAF2/3/5 sig-
nalling pathway might be compensating for the loss of
CD40-TRAF6 signalling, and the function of only one of
the CD40 signalling pathways could be sufficient for
CD40 signalling in EAE.
Another explanation may be found in the specificity of
our SMI for monocytes and macrophages. Although macro-
phages play a major role in EAE, EAE is also a T-cell driven
disease. Here we show that our SMI is able to interfere with
monocyte/macrophage transendothelial migration, but is
not sufficient to strongly decrease disease severity, suggest-
ing that the T-cell component is still causing disease symp-
toms. It may therefore be interesting to use the SMI,
targeting monocytes and macrophages, in co-treatment
with T cell-targeting drugs, such as interferons, in MS.
Another approach is to think of improvements in our
SMI to target the T cell-mediated characteristics in EAE.
As described by Becher et al., CD40 expressed by CNS-
endogenous cells controls the migration and retention of
MOG-reactive T cells in the CNS of mice during EAE
[20]. It is possible that our SMI does not cross the BBB
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and only affects peripheral monocytes and not the
microglia, which in turn could explain why we only see
a reduction in infiltrating macrophages and not in T
cells. Therefore, it could be interesting to investigate
whether cell type-specific delivery of our SMI to micro-
glia may be an attractive strategy to increase its efficacy
in vivo. A nanomedicine-based approach could be of
interest to achieve delivery of the inhibitors across the
BBB to microglia [53].
Conclusions
In conclusion, we have shown that small molecule-
mediated inhibition of the CD40-TRAF6 interaction lim-
ited ROS production by human monocytes and reduced
migration of human monocytes across an in vitro BBB.
The CD40-TRAF6 SMI reduced severity of symptoms of
EAE in rats, but not in mice, suggesting that inhibiting
monocyte-derived macrophage infiltration into the CNS
is not sufficient to fully prevent clinical symptoms of
EAE. Our SMI can therefore be considered as co-
treatment to inhibit monocyte recruitment in MS.
Additional files
Additional file 1: Figure S1. Immune cell accumulation in the spinal
cords of EAE rats is reduced by SMI 6877002 treatment. Gene expression
in the rat spinal cord after recovery was measured by qPCR. mRNA
expression levels of TNF, NOS2, MMP2, MMP9, and CD80 presented as
relative expression compared to GAPDH. Experiments were performed in
eight animals per group, after recovery of EAE. Results are presented as the
mean ± SEM, **P < 0.01 as determined by Student’s t test. (TIF 15382 kb)
Additional file 2: Figure S2. Flow cytometry of circulating leukocytes is
not affected by SMI treatment. Immune cell subsets measured in (A)
blood and (B) spleen. Experiments were performed with six animals of
either EAE or SMI group and three animals in the control group. Results
are presented as the mean ± SEM. (TIF 78393 kb)
Additional file 3: Figure S3. mRNA gene expression at the peak of EAE
in the spinal cord of mice is not affected by SMI 6877002 treatment. TNF,
IFN-γ, MCP-1, IL-17, IL-10, and FoxP3 mRNA gene expression in the spinal
cord determined by real-time quantitative PCR and presented as relative
expression compared to GAPDH/CycloA/Rplp0. Experiments were per-
formed with six animals of either EAE or SMI group and three animals in
the control group. Results are presented as the mean ± SEM,*P < 0.05, **P
< 0.01, ***P < 0.001, as determined by Student’s t test. (TIF 23399 kb)
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